Figure 3 | Gene Therapy

Figure 3

From: Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system

Figure 3

The mean tumor volume±s.d. (a) and the Kaplan–Meier survival curves (b) of nude mice bearing human colon carcinoma xenografts after implantation of control or factory neovessels. HCT-116 cells (2 × 106) were injected s.c. into the dorsal skin of nude mice (n=5 mice per group). At 5 days after cell inoculation, either control neovessels (group A) or factory neovessels (groups B and C) were implanted s.c. in the ventral area. At days 10 and 25 mice from groups A and B received an i.v. injection of 2 × 106 human peripheral blood lymphocytes (PBLs). Mice from group C received phosphate-buffered saline (PBS) instead of lymphocytes. Mice from group B showed significant tumor growth inhibition (P=0.02) and survived significantly longer (P=0.0333) than control mice.

Back to article page